Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022

Описание к видео Subcutaneous Epcoritamab for Richter's Syndrome - Dr. Arnon Kater ASH 2022

Early results from a clinical trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients whose chronic lymphocytic leukemia (CLL) has progressed to Richter’s syndrome.

Dr. Arnon Kater from Cancer Center Amsterdam and colleagues presented the results at the American Society for Hematology Annual Meeting in 2022.

Read the full article on CLL Society's website at: https://cllsociety.org/2023/04/dr-arn...
__________________________________________________________________________________________
CLL Society Website: https://cllsociety.org/
Facebook:   / cllsociety  
Twitter:   / cllsociety  
LinkedIn:   / cll-society  

Комментарии

Информация по комментариям в разработке

Похожие видео